This designation follows early clinical success, as data from a Phase 1-2 trial demonstrated promising anti-tumor activity alongside a manageable safety profile. These findings served as the foundation for the design of a larger, ongoing Phase 3 trial. The designation focuses specifically on addressing the significant medical needs associated with metastatic PDAC, a condition where options remain limited for many patients.

Regulators reserve this status for medicines that show substantial improvement over existing therapies in treating serious conditions. Rasonque already holds FDA approval for adult patients who have undergone at least one round of systemic therapy or are ineligible for multiagent treatments. By fast-tracking the review process, the company hopes to bring this targeted therapy to market more efficiently.